PMID- 30073758
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20240331
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 7
IP  - 9
DP  - 2018 Sep
TI  - The efficacy of Stereotactic body radiation therapy and the impact of systemic 
      treatments in oligometastatic patients from prostate cancer.
PG  - 4379-4386
LID - 10.1002/cam4.1707 [doi]
AB  - BACKGROUND: Diagnoses of oligometastatic prostate cancer (PC) increased in the 
      recent years thanks to the advancement in imaging and more effective systemic 
      therapies. Here we evaluate the efficacy of Stereotactic Body Radiation Therapy 
      (SBRT) in oligorecurrent and oligoprogressive PC. METHODS: We included patients 
      with a maximum of five metastases diagnosed in a maximum of two target organs. 
      Concomitant treatment with hormonal therapies or chemotherapies was allowed. End 
      points of the present study were the outcome in terms of Local control of treated 
      metastases (LC), out-field progression free survival, overall progression free 
      survival (PFS), and overall survival. RESULTS: We included in the analysis 64 
      patients treated on 90 metastases. Fifty (78.1%) patients were treated on lymph 
      nodes, 2 (3.1%) patients simultaneously on lymph node and bone while 10 (15.7%) 
      patients on bone only. Lung metastases were treated in 2 (3.1%) patients. 
      Thirty-seven (57.81%) were without androgen deprivation therapy when treated with 
      SBRT. Median follow-up was 15.2 months. Rates of LC at 6-, 12-, and 18- months 
      were 94%, 88%, and 84%, respectively. Oligoprogressive patients compared to 
      oligorecurrent (HR 9.10, P = 0.049) and prolongation of time from diagnosis of 
      metastases to SBRT (HR 1.03, P = 0.047) were associated with worse LC. Median PFS 
      was 6.6 months (range 1.1-42.4). Castration resistant patients experienced worse 
      PFS compared to castration sensitive group (HR 2.12, P = 0.021). CONCLUSIONS: 
      Stereotactic body radiation therapy seems to be an effective treatment for 
      metastases from PC. Prospective trials are necessary to better define selection 
      of patients and to evaluate combination of SBRT and new systemic drugs in 
      castration resistant patients.
CI  - (c) 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Franzese, Ciro
AU  - Franzese C
AUID- ORCID: 0000-0001-6893-6284
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
FAU - Zucali, Paolo Andrea
AU  - Zucali PA
AUID- ORCID: 0000-0002-2274-1702
AD  - Medical Oncology and Hematology Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
FAU - Di Brina, Lucia
AU  - Di Brina L
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
FAU - D'Agostino, Giuseppe
AU  - D'Agostino G
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
FAU - Navarria, Pierina
AU  - Navarria P
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
FAU - Franceschini, Davide
AU  - Franceschini D
AUID- ORCID: 0000-0003-1142-2439
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
FAU - Santoro, Armando
AU  - Santoro A
AD  - Medical Oncology and Hematology Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan-Rozzano, Italy.
FAU - Scorsetti, Marta
AU  - Scorsetti M
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research 
      Hospital, Milan-Rozzano, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan-Rozzano, Italy.
LA  - eng
PT  - Journal Article
DEP - 20180802
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Combined Modality Therapy
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging/methods
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prostatic Neoplasms/diagnostic imaging/*pathology/*radiotherapy
MH  - *Radiosurgery/methods
MH  - Treatment Outcome
PMC - PMC6144154
OTO - NOTNLM
OT  - hormonal therapy
OT  - oligometastases
OT  - prostate cancer
OT  - stereotactic body radiation therapy
OT  - systemic treatment
EDAT- 2018/08/04 06:00
MHDA- 2019/11/15 06:00
PMCR- 2018/08/02
CRDT- 2018/08/04 06:00
PHST- 2018/05/12 00:00 [received]
PHST- 2018/07/05 00:00 [revised]
PHST- 2018/07/06 00:00 [accepted]
PHST- 2018/08/04 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2018/08/04 06:00 [entrez]
PHST- 2018/08/02 00:00 [pmc-release]
AID - CAM41707 [pii]
AID - 10.1002/cam4.1707 [doi]
PST - ppublish
SO  - Cancer Med. 2018 Sep;7(9):4379-4386. doi: 10.1002/cam4.1707. Epub 2018 Aug 2.